Metformin
- Generic Name
- Metformin
- Brand Names
- Actoplus Met, Avandamet, Fortamet, Glucophage, Glucovance, Glumetza, Glycon, Invokamet, Janumet, Jentadueto, Kazano, Kombiglyze, Komboglyze, Qternmet, Riomet, Segluromet, Synjardy, Trijardy, Velmetia, Xigduo
- Drug Type
- Small Molecule
- Chemical Formula
- C4H11N5
- CAS Number
- 657-24-9
- Unique Ingredient Identifier
- 9100L32L2N
- Background
Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes.
...
- Indication
Metformin immediate-release formulations
Metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients ≥10 years old with type 2 diabetes mellitus.
Metformin extended-release tablet (XR)
...
- Associated Conditions
- Cardiovascular Mortality, End Stage Renal Disease (ESRD), Hospitalizations, Polycystic Ovarian Syndrome (PCOS), Type 2 Diabetes Mellitus, Decreased estimated glomerular filtration rate
- Associated Therapies
- -
Evaluation of the Effects of Diosmin/Hespiridin Combination on the Clinical Outcomes in Patients With Polycystic Ovary Syndrome
- Conditions
- Interventions
- First Posted Date
- 2023-10-16
- Last Posted Date
- 2023-10-16
- Lead Sponsor
- Ain Shams University
- Target Recruit Count
- 120
- Registration Number
- NCT06083935
Research Study to Compare Semaglutide Tablets With Empagliflozin or Metformin Tablets in People With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2023-10-16
- Last Posted Date
- 2024-02-26
- Lead Sponsor
- Novo Nordisk A/S
- Registration Number
- NCT06083675
- Locations
- 🇹🇭
Songklanagarind Hospital, Songkla, Thailand
🇬🇷General Hospital of Thessaloniki "G.Papanikolaou", Thessaloniki, Greece
🇵🇱ETG Siedlce, Siedlce, Masovian, Poland
A Study to Evaluate the DDI of HSK7653 With Metformin
- First Posted Date
- 2023-10-16
- Last Posted Date
- 2023-10-16
- Lead Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 22
- Registration Number
- NCT06084156
- Locations
- 🇨🇳
Peking University Third Hospital, Beijing, Beijing, China
The Effect of Addition of Metformin to SGLT2 In Diabetic Patients With Heart Failure With Preserved Ejection Fraction
- Conditions
- Interventions
- First Posted Date
- 2023-10-12
- Last Posted Date
- 2023-10-12
- Lead Sponsor
- October University for Modern Sciences and Arts
- Target Recruit Count
- 80
- Registration Number
- NCT06080802
- Locations
- 🇪🇬
clinical research uint- El-sheikh zayed specialized hospital SMC- Egyptian Ministry of health, Cairo, Egypt
Potential Drug Interaction Study Between Vemircopan and Rosuvastatin, Metformin, Levonorgestrel/Ethinyl Estradiol-containing Oral Contraceptives, and Carbamazepine
- Conditions
- Interventions
- First Posted Date
- 2023-10-06
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT06071442
- Locations
- 🇺🇸
Research Site, Brooklyn, Maryland, United States
A DDI Study of JMKX000623 and Metformin Hydrochloride
- First Posted Date
- 2023-10-04
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Jemincare
- Target Recruit Count
- 24
- Registration Number
- NCT06066060
- Locations
- 🇨🇳
Huashan Hospital Fudan University, Shanghai, Shanghai, China
The Effect of Henagliflozin and Metformin on Myocardial Tissue-level Characteristics
- Conditions
- Interventions
- First Posted Date
- 2023-09-28
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 64
- Registration Number
- NCT06059287
CRD vs. Met in Patients With Obese PCOS Infertility
- Conditions
- Interventions
- First Posted Date
- 2023-09-22
- Last Posted Date
- 2023-09-22
- Lead Sponsor
- Shanghai First Maternity and Infant Hospital
- Target Recruit Count
- 406
- Registration Number
- NCT06049186
- Locations
- 🇨🇳
Shanghai First Maternity and Infant Hospital, Shanghai, Shanghai, China
ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin)
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Susanna Naggie, MD
- Target Recruit Count
- 15000
- Registration Number
- NCT06042855
- Locations
- 🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇺🇸Olivo Wellness Medical Center, Chicago, Illinois, United States
🇺🇸Boston Medical Center, Boston, Massachusetts, United States
A Feasibility Study Evaluating a Role for Maintenance Therapy in Patients With Biochemically Progressive Castration Sensitive Prostate Cancer on Intermittent Androgen Deprivation Therapy
- Conditions
- Interventions
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- University of Arkansas
- Target Recruit Count
- 30
- Registration Number
- NCT06044025
- Locations
- 🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.